This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Ticker(s): IDRSFWho's the expert?
Institution: Roper St. Francis Physician Partners Endocrinology
- Board certified in Endocrinology
- practices the full range of endocrinology with special interests in diabetes, thyroid issues and calcium disorders
- Treats 250 patients with Hypogonadism and is very familiar with TLANDO
Interview GoalDiscussing the current treatment landscape for resistant hypertension and PRECISION, the Phase 3 study investigating Aprocitentan, a dual endothelin receptor antagonist.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
